Immunomedics Inc. (NASDAQ:IMMU) traded up 3.6% on Friday . The stock traded as high as $2.28 and last traded at $2.28, with a volume of 607,062 shares traded. The stock had previously closed at $2.20.

Several equities research analysts have recently weighed in on the company. Wells Fargo & Co. reissued a “buy” rating on shares of Immunomedics in a research note on Tuesday, May 24th. Jefferies Group reissued a “buy” rating and set a $5.00 price objective on shares of Immunomedics in a research note on Monday, June 6th. Finally, Zacks Investment Research lowered Immunomedics from a “buy” rating to a “sell” rating in a research note on Tuesday, May 10th.

The firm has a 50 day moving average of $2.95 and a 200-day moving average of $2.78. The company’s market capitalization is $216.15 million.

Immunomedics (NASDAQ:IMMU) last announced its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.02. On average, equities research analysts anticipate that Immunomedics Inc. will post ($0.57) earnings per share for the current year.

In other news, Chairman David M. Goldenberg sold 353,010 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $3.88, for a total value of $1,369,678.80. Following the transaction, the chairman now directly owns 2,602,063 shares of the company’s stock, valued at approximately $10,096,004.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cynthia L. Goldenberg sold 371,990 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $3.03, for a total value of $1,127,129.70. Following the completion of the transaction, the chief executive officer now directly owns 650,396 shares in the company, valued at $1,970,699.88. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Immunomedics stock. Marshall Wace LLP bought a new stake in Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned approximately 0.90% of Immunomedics at the end of the most recent reporting period.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.